ADBE
Adobe Inc.
ADBE's fundamentals are strong and it looks cheap: trading at 13x earnings, about a third of its usual 43x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ADBE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ADBE's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ADBE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.9x | $239 | — |
| Current | 13x | $239 | — |
| Cheap | 22x | $396 | +66% |
| Fair | 43x | $771 | +223% |
| Expensive | 54x | $972 | +308% |
Historical ranges are pointers, not guarantees.
ADBE's PE is in its cheap range at 13x. If earnings grow as analysts expect, today's price would be 8.9x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ADBE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
ADBE has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ADBE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.84 | +50% |
| Q3 2026 | $17.91 | +12% |
| Q2 2026 | $17.47 | +12% |
| Q1 2026 | $17.16 | +13% |
| Q4 2025 | $16.70 | +35% |
| Q3 2025 | $16.01 | +35% |
| Q2 2025 | $15.59 | +40% |
| Q1 2025 | $15.14 | +45% |
| Q4 2024 | $12.36 | +4.6% |
ADBE has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ADBE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.8B | +13% |
| Q2 2026 | $6.6B | +13% |
| Q1 2026 | $6.4B | +12% |
| Q4 2025 | $6.2B | +10% |
| Q3 2025 | $6B | +11% |
| Q2 2025 | $5.9B | +11% |
| Q1 2025 | $5.7B | +10% |
| Q4 2024 | $5.6B | +11% |
ADBE's revenue has grown year over year every quarter since late 2020: $6.8B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -1.5 points |
| Q2 2026 | 34% | -2.1 points |
| Q1 2026 | 38% | -0.1 points |
| Q4 2025 | 37% | +1.6 points |
| Q3 2025 | 36% | -0.5 points |
| Q2 2025 | 36% | +0.4 points |
| Q1 2025 | 38% | +20 points |
| Q4 2024 | 35% | +0.4 points |
ADBE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ADBE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ADBE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.4B | +15% |
| Q2 2026 | $2.1B | -1.7% |
| Q1 2026 | $2.9B | +19% |
| Q4 2025 | $3.1B | +8.8% |
| Q3 2025 | $2.1B | +8.2% |
| Q2 2025 | $2.1B | +13% |
| Q1 2025 | $2.5B | +116% |
| Q4 2024 | $2.9B | +85% |
ADBE's free cash flow has been positive every quarter for seven years: $10.6B over the past year, up 10% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ADBE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -7M shares |
| 1 year | -6.7% | -28.6M shares |
| 3 years | -14% | -64M shares |
| 5 years | -18% | -85.2M shares |
| Available history | -20% | -96.1M shares |
ADBE has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2B |
| Q2 2026 | $2.1B |
| Q1 2026 | $2.5B |
| Q4 2025 | $2.5B |
| Q3 2025 | $2.1B |
| Q2 2025 | $3.5B |
| Q1 2025 | $3.3B |
| Q4 2024 | $2.5B |
ADBE spent $9.3B buying back its own shares over the past year, down 18% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ADBE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
ADBE's net debt is less than a year of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ADBE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 25.8 | Neutral |
ADBE's weekly RSI is 45 (neutral) and its Stochastic is 26 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ADBE PE vs Technology Sector
| Metric | ADBE | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 28x | 52% below |
| PE % | 3 | 35 | 32 pts below |
ADBE is trading at 13x earnings, a 52% discount to the Technology sector's median of 28x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ADBE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $244.1 | 2.3% below |
| 20 week MA | $248.6 | 4.1% below |
| 50 week MA | $261.6 | 8.8% below |
| 100 week MA | $321.8 | 26% below |
| 200 week MA | $410.6 | 42% below |
ADBE is in a downtrend: it's below all five of its weekly moving averages, and 42% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ADBE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.8 | $499.9 | +51% |
| 2021 | $499.9 | $569.6 | +14% |
| 2022 | $569.6 | $338.5 | -41% |
| 2023 | $338.5 | $596.6 | +76% |
| 2024 | $596.6 | $446.5 | -25% |
| 2025 | $446.5 | $353.8 | -21% |
| 2026 YTD | $353.8 | $238.5 | -33% |
ADBE has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.